| Rank |
Drug |
Current Manufacturer |
Total Sales ($000) |
% Change 2007 |
| 1 |
Lipitor
| Pfizer Inc |
5,880,128 |
-4.6% |
| 2 |
Nexium
| AstraZeneca Pharmaceuticals |
4,794,450 |
10.1% |
3 ( 2) |
Plavix
| Bristol-Myers Squibb Company |
3,796,221 |
23.1% |
4 ( 1) |
Advair Diskus
| GlaxoSmithKline |
3,572,473 |
5.4% |
5 ( 1) |
Prevacid
| Takeda Pharmaceuticals North America, Inc |
3,295,465 |
-0.6% |
6 ( 1) |
Seroquel
| AstraZeneca Pharmaceuticals |
2,908,971 |
15.5% |
7 ( 1) |
Singulair
| Merck & Co., Inc. |
2,898,060 |
1.2% |
| 8 |
Effexor XR
| Wyeth |
2,657,729 |
7.8% |
9 ( 24) |
OxyContin
| Purdue Pharma LP |
2,502,982 |
139.8% |
| 10 |
Actos
| Takeda Pharmaceuticals North America, Inc |
2,447,602 |
9.8% |
11 ( 2) |
Lexapro
| Forest Pharmaceuticals, Inc |
2,412,048 |
4.7% |
12 ( 3) |
Abilify
| Bristol-Myers Squibb Company |
2,371,795 |
33.1% |
| 13 |
Topamax
| Janssen Pharmaceuticals, Inc |
2,177,348 |
18.5% |
14 ( 2) |
Cymbalta
| Eli Lilly and Company |
2,170,162 |
25.2% |
15 ( 3) |
Zyprexa
| Eli Lilly and Company |
1,748,259 |
10.7% |
16 ( 6) |
Valtrex
| GlaxoSmithKline |
1,684,192 |
20.7% |
17 ( 6) |
Crestor
| AstraZeneca Pharmaceuticals |
1,676,553 |
22.6% |
18 ( 6) |
Vytorin
| Merck & Co., Inc. |
1,545,643 |
-20.3% |
19 ( 2) |
Lamictal
| GlaxoSmithKline |
1,539,101 |
-10.4% |
| 20 |
Celebrex
| Pfizer Inc |
1,526,818 |
7.8% |
21 ( 5) |
Lantus
| Sanofi-Aventis |
1,475,110 |
13.2% |
22 ( 3) |
Levaquin
| Janssen Pharmaceuticals, Inc |
1,461,080 |
2.0% |
23 ( 4) |
Adderall XR
| Shire US Inc |
1,446,629 |
12.2% |
24 ( 13) |
Lyrica
| Pfizer Inc |
1,389,205 |
38.9% |
25 ( 3) |
Diovan
| Novartis Corporation |
1,283,141 |
14.8% |
26 ( 4) |
Tricor
| Abbott Laboratories |
1,249,299 |
12.9% |
27 ( 9) |
Flomax
| Boehringer Ingelheim Pharmaceuticals, Inc |
1,236,963 |
23.4% |
28 ( 14) |
Risperdal
| Janssen Pharmaceuticals, Inc |
1,221,505 |
-31.8% |
29 ( 3) |
Diovan HCT
| Novartis Corporation |
1,212,308 |
15.3% |
30 ( 9) |
Zetia
| Schering-Plough |
1,183,627 |
-15.8% |
31 ( 8) |
Aricept
| Eisai Corporation |
1,149,221 |
16.9% |
32 ( 15) |
Spiriva
| Boehringer Ingelheim Pharmaceuticals, Inc |
1,142,746 |
31.6% |
33 ( 1) |
Concerta
| Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
1,103,973 |
7.1% |
34 ( 3) |
Aciphex
| Eisai Corporation |
1,052,133 |
-4.3% |
35 ( 5) |
Imitrex Oral
| GlaxoSmithKline |
972,778 |
2.3% |
36 ( 13) |
Lidoderm
| Endo Pharmaceuticals |
970,208 |
20.1% |
37 ( 20) |
Keppra
| UCB Inc. |
940,941 |
32.8% |
38 ( 10) |
Viagra
| Pfizer Inc |
920,051 |
11.5% |
39 ( 22) |
Atripla
| Gilead Sciences, Inc. |
915,561 |
48.3% |
40 ( 13) |
Lovenox
| Sanofi-Aventis |
913,764 |
22.5% |
41 ( 43) |
Januvia
| Merck & Co., Inc. |
913,501 |
93.7% |
42 ( 1) |
Nasonex
| Schering-Plough |
904,074 |
1.3% |
43 ( 2) |
Ambien CR
| Sanofi-Aventis |
865,719 |
-1.2% |
44 ( 10) |
Provigil
| Cephalon, Inc. |
846,089 |
13.6% |
45 ( 13) |
Geodon Oral
| Pfizer Inc |
797,100 |
19.9% |
46 ( 16) |
Truvada
| Gilead Sciences, Inc. |
775,787 |
28.0% |
47 ( 8) |
Lunesta
| Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc) |
771,019 |
8.2% |
48 ( 2) |
Enbrel
| Amgen Inc. |
763,927 |
-12.7% |
49 ( 1) |
Actonel
| Procter & Gamble |
714,977 |
-9.6% |
50 ( 13) |
CellCept
| Roche Pharmaceuticals |
711,530 |
18.7% |
51 ( 14) |
Humalog
| Eli Lilly and Company |
702,798 |
18.7% |
52 ( 8) |
Detrol LA
| Pfizer Inc |
696,934 |
9.6% |
53 ( 13) |
Depakote ER
| Abbott Laboratories |
692,472 |
20.0% |
54 ( 5) |
Cozaar
| Merck & Co., Inc. |
690,028 |
5.8% |
55 ( 9) |
Pulmicort Respules
| AstraZeneca Pharmaceuticals |
651,024 |
9.9% |
56 ( 14) |
Niaspan
| Abbott Laboratories |
638,816 |
16.9% |
57 ( 19) |
Wellbutrin XL
| Valeant Pharmaceuticals International |
613,694 |
-38.2% |
58 ( 7) |
Chantix
| Pfizer Inc |
605,323 |
-20.8% |
59 ( 13) |
Budeprion XL
| Teva Pharmaceuticals |
595,206 |
10.8% |
60 ( 11) |
Byetta
| Amylin Pharmaceuticals, Inc. |
594,736 |
9.9% |
61 ( 69) |
Yaz
| Bayer Healthcare Pharmaceuticals |
585,421 |
129.9% |
62 ( 17) |
Prograf
| Astellas Pharma US |
584,703 |
13.3% |
63 ( 20) |
Namenda
| Forest Pharmaceuticals, Inc |
582,468 |
18.9% |
64 ( 16) |
Arimidex
| AstraZeneca Pharmaceuticals |
568,846 |
12.3% |
65 ( 9) |
Combivent
| Boehringer Ingelheim Pharmaceuticals, Inc |
558,351 |
4.6% |
66 ( 20) |
Cialis
| Eli Lilly and Company |
555,080 |
22.5% |
67 ( 10) |
Flovent HFA
| GlaxoSmithKline |
553,050 |
6.1% |
68 ( 57) |
Protonix
| Wyeth |
552,903 |
-74.1% |
69 ( 1) |
Premarin Tabs
| Wyeth |
548,917 |
-1.5% |
70 ( 50) |
Suboxone
| Reckitt Benckiser Pharmaceuticals Inc. |
531,808 |
88.4% |
71 ( 11) |
Hyzaar
| Merck & Co., Inc. |
528,401 |
5.7% |
72 ( 19) |
ProAir HFA
| Teva Pharmaceuticals |
527,655 |
25.3% |
73 ( 14) |
Reyataz
| Bristol-Myers Squibb Company |
519,398 |
18.4% |
74 ( 19) |
Benicar HCT
| Daiichi Sankyo |
515,213 |
24.4% |
75 ( 6) |
Synthroid
| Abbott Laboratories |
514,887 |
-6.0% |
76 ( 47) |
Avandia
| GlaxoSmithKline |
513,715 |
-53.7% |
77 ( 19) |
Boniva
| Genentech, Inc |
512,179 |
26.7% |
78 ( 5) |
Strattera
| Eli Lilly and Company |
511,612 |
-4.5% |
79 ( ) |
Polymagma Plain
| |
507,096 |
NA |
80 ( 2) |
Skelaxin
| Elan Corporation |
501,310 |
-3.1% |
| 81 |
Evista
| Eli Lilly and Company |
499,924 |
-0.7% |
82 ( 10) |
Asacol
| Procter & Gamble |
463,747 |
10.2% |
83 ( 16) |
Depakote
| Abbott Laboratories |
456,909 |
-20.4% |
84 ( 4) |
Xalatan
| Pfizer Inc |
456,321 |
5.9% |
| 85 |
Humira
| Abbott Laboratories |
455,911 |
-1.4% |
86 ( 16) |
Benicar
| Daiichi Sankyo |
455,408 |
23.2% |
87 ( 12) |
Gleevec
| Novartis Corporation |
450,576 |
17.2% |
88 ( 15) |
AndroGel
| Abbott Laboratories |
441,168 |
20.5% |
89 ( 26) |
Enbrel Sureclick
| Amgen Inc. |
433,792 |
47.9% |
| 90 |
Avelox
| Bayer Healthcare Pharmaceuticals |
428,793 |
1.0% |
91 ( 3) |
Fentanyl Oral Citrate
| |
423,743 |
3.8% |
92 ( 39) |
Lovaza
| GlaxoSmithKline |
417,542 |
65.2% |
93 ( 20) |
RenaGel
| Genzyme Corporation |
408,552 |
39.2% |
94 ( 4) |
Avapro
| Bristol-Myers Squibb Company |
405,557 |
5.4% |
95 ( 67) |
Humira Pen
| Abbott Laboratories |
381,397 |
99.4% |
96 ( ) |
Vyvanse
| Shire US Inc |
374,990 |
486.1% |
97 ( 3) |
Kaletra
| Abbott Laboratories |
373,122 |
0.0% |
98 ( 6) |
Xopenex
| Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc) |
371,995 |
4.9% |
99 ( 13) |
Copaxone
| Sanofi-Aventis |
370,479 |
22.1% |
100 ( 21) |
Avodart
| GlaxoSmithKline |
364,706 |
29.6% |
101 ( 13) |
Femara
| Novartis Corporation |
360,993 |
23.0% |
102 ( 5) |
Avalide
| Bristol-Myers Squibb Company |
355,748 |
8.2% |
103 ( 2) |
Ortho Tri-Cyclen Lo
| Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
350,375 |
-5.7% |
104 ( 23) |
Sensipar
| Amgen Inc. |
348,365 |
30.8% |
105 ( 13) |
Aldara
| Medicis Pharmaceutical Corporation |
347,587 |
20.9% |
106 ( 10) |
NovoLog Mix 70/30
| Novo Nordisk Inc. |
347,106 |
18.7% |
107 ( 18) |
Restasis
| Allergan, Inc |
339,110 |
23.4% |
108 ( 24) |
Mirapex
| Boehringer Ingelheim Pharmaceuticals, Inc |
335,293 |
34.2% |
109 ( 33) |
Yasmin 28
| Bayer Healthcare Pharmaceuticals |
328,905 |
-37.7% |
110 ( 33) |
Solodyn
| Medicis Pharmaceutical Corporation |
316,079 |
40.8% |
111 ( ) |
Lantus SoloSTAR
| Sanofi-Aventis |
315,946 |
829.5% |
112 ( 11) |
Norvir
| Abbott Laboratories |
311,245 |
13.1% |
113 ( 20) |
Focalin XR
| Novartis Corporation |
310,010 |
24.5% |
114 ( 26) |
Actoplus Met
| Takeda Pharmaceuticals North America, Inc |
301,258 |
31.1% |
115 ( 37) |
Vesicare
| Astellas Pharma US |
299,147 |
45.5% |
116 ( 3) |
Forteo
| Eli Lilly and Company |
291,621 |
3.3% |
117 ( 7) |
Allegra-D 12 Hour
| Sanofi-Aventis |
288,202 |
-9.0% |
118 ( 13) |
Procrit
| Centocor Ortho Biotech, Inc |
287,898 |
-18.5% |
119 ( 11) |
Nasacort AQ
| Sanofi-Aventis |
285,359 |
-10.4% |
120 ( 8) |
Tarceva
| Genentech, Inc |
276,875 |
4.9% |
121 ( 12) |
Combivir
| GlaxoSmithKline |
275,844 |
-13.3% |
122 ( ) |
Tamiflu
| Genentech, Inc |
275,121 |
138.3% |
123 ( 3) |
Avonex
| Biogen Idec |
273,303 |
2.4% |
124 ( 13) |
NuvaRing
| Merck & Co., Inc. |
267,259 |
15.9% |
125 ( 74) |
Coreg CR
| GlaxoSmithKline |
265,844 |
83.5% |
126 ( 10) |
Epzicom
| GlaxoSmithKline |
265,252 |
15.0% |
127 ( ) |
Levemir
| Novo Nordisk Inc. |
256,142 |
103.5% |
128 ( 17) |
Duragesic
| |
251,699 |
-17.8% |
129 ( 31) |
Risperdal Consta
| Janssen Pharmaceuticals, Inc |
250,948 |
29.5% |
130 ( 5) |
Zyvox
| Pfizer Inc |
249,712 |
5.6% |
131 ( 36) |
Tussionex
| Sanofi-Aventis |
246,583 |
37.5% |
132 ( ) |
Invega
| Janssen Pharmaceuticals, Inc |
246,052 |
146.4% |
133 ( 109) |
Fosamax
| Merck & Co., Inc. |
244,850 |
-81.9% |
134 ( 29) |
Kadian
| Actavis |
244,504 |
27.9% |
135 ( 23) |
Levitra
| Bayer Healthcare Pharmaceuticals |
239,860 |
21.4% |
136 ( 28) |
Differin
| Galderma Laboratories |
239,747 |
27.4% |
137 ( 9) |
Astelin
| Meda Pharmaceuticals |
239,404 |
9.1% |
138 ( 3) |
Lumigan
| Allergan, Inc |
238,436 |
5.1% |
139 ( ) |
Symbicort
| AstraZeneca Pharmaceuticals |
237,955 |
683.9% |
140 ( ) |
Janumet
| Merck & Co., Inc. |
237,426 |
379.2% |
141 ( 15) |
Xeloda
| Genentech, Inc |
236,302 |
17.3% |
142 ( 25) |
Clarinex
| Schering-Plough |
233,417 |
-19.2% |
143 ( ) |
Proventil HFA
| Schering-Plough |
227,833 |
66.4% |
144 ( 9) |
Humalog Mix 75/25 Pn
| |
226,996 |
11.1% |
145 ( 2) |
BenzaClin
| Sanofi-Aventis |
225,984 |
6.0% |
146 ( 5) |
Vigamox
| Alcon Laboratories, Inc. |
220,720 |
6.6% |
147 ( 8) |
Fosamax Plus D
| Merck & Co., Inc. |
218,738 |
-4.9% |
148 ( 21) |
Maxalt
| Merck & Co., Inc. |
218,686 |
23.7% |
149 ( 15) |
Cosopt
| Merck & Co., Inc. |
218,315 |
-10.1% |
150 ( 55) |
Requip
| GlaxoSmithKline |
213,127 |
-47.7% |
151 ( 3) |
Relpax
| Pfizer Inc |
213,123 |
0.3% |
152 ( 23) |
Patanol
| Alcon Laboratories, Inc. |
211,608 |
-18.2% |
153 ( 3) |
Casodex
| AstraZeneca Pharmaceuticals |
210,830 |
1.6% |
154 ( 22) |
Welchol
| Daiichi Sankyo |
209,309 |
29.4% |
155 ( 17) |
Ciprodex Otic
| Alcon Laboratories, Inc. |
207,845 |
19.3% |
156 ( 7) |
Viread
| Gilead Sciences, Inc. |
207,458 |
-1.6% |
157 ( 8) |
Catapres-TTS
| Boehringer Ingelheim Pharmaceuticals, Inc |
204,665 |
9.2% |
158 ( ) |
Loestrin 24 Fe
| Warner Chilcott |
200,272 |
42.0% |
159 ( 15) |
Thalomid
| Celgene Corporation |
198,528 |
-10.9% |
160 ( 6) |
Alphagan P
| Allergan, Inc |
195,794 |
5.2% |
161 ( 2) |
Endocet
| Endo Pharmaceuticals |
194,559 |
0.3% |
162 ( ) |
Revlimid
| Celgene Corporation |
194,505 |
99.8% |
163 ( 39) |
Avandamet
| GlaxoSmithKline |
192,785 |
-29.9% |
164 ( 13) |
Maxalt MLT
| |
192,378 |
19.0% |
165 ( 109) |
Altace
| King Pharmaceuticals, Inc. (now part of Pfizer - October 2010) |
191,053 |
-73.1% |
166 ( 11) |
Budeprion SR
| Teva Pharmaceuticals |
188,956 |
-6.2% |
167 ( 16) |
Pegasys
| Genentech, Inc |
188,011 |
20.5% |
168 ( 16) |
Ultram ER
| Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
185,318 |
19.2% |
169 ( 25) |
Fentora
| Cephalon, Inc. |
185,244 |
25.6% |
170 ( 8) |
Asmanex
| Schering-Plough |
185,244 |
14.9% |
171 ( 29) |
Rhinocort Aqua
| AstraZeneca Pharmaceuticals |
184,397 |
-18.3% |
172 ( 1) |
Temodar
| Schering-Plough |
183,005 |
5.5% |
173 ( 18) |
Micardis HCT
| Abbott Laboratories |
180,407 |
21.8% |
174 ( ) |
Sotret
| Ranbaxy Pharmaceuticals Inc. |
176,782 |
35.3% |
175 ( 21) |
Trizivir
| GlaxoSmithKline |
176,538 |
-13.1% |
176 ( 19) |
Enablex
| Warner Chilcott |
176,293 |
19.6% |
177 ( ) |
Isentress
| Merck & Co., Inc. |
175,457 |
>999 |
178 ( 4) |
Tobradex
| Alcon Laboratories, Inc. |
175,251 |
1.4% |
179 ( 104) |
Trileptal
| Novartis Corporation |
170,422 |
-68.0% |
180 ( 23) |
Sustiva
| Bristol-Myers Squibb Company |
169,984 |
-15.0% |
181 ( ) |
Amitiza
| Takeda Pharmaceuticals North America, Inc |
169,610 |
41.3% |
182 ( ) |
Micardis
| Boehringer Ingelheim Pharmaceuticals, Inc |
165,979 |
18.7% |
183 ( 3) |
Zovirax Topical
| GlaxoSmithKline |
164,974 |
8.6% |
184 ( ) |
Ocella
| |
164,399 |
NA |
185 ( ) |
Propecia
| Merck & Co., Inc. |
163,166 |
13.7% |
186 ( ) |
Taclonex
| Warner Chilcott |
161,674 |
23.4% |
187 ( 49) |
Actiq
| Abbott Laboratories |
161,532 |
-29.8% |
188 ( ) |
Valcyte
| Roche Pharmaceuticals |
160,605 |
15.3% |
189 ( 7) |
Klor-Con
| Upsher-Smith Laboratories Inc. |
159,584 |
0.2% |
190 ( 11) |
Atacand
| AstraZeneca Pharmaceuticals |
159,583 |
-0.7% |
191 ( ) |
Doryx
| Pfizer Inc |
158,466 |
20.4% |
192 ( ) |
Veramyst
| GlaxoSmithKline |
158,347 |
289.8% |
193 ( 4) |
Avinza
| King Pharmaceuticals, Inc. (now part of Pfizer - October 2010) |
157,224 |
7.9% |
194 ( 1) |
Allegra-D 24 Hour
| Sanofi-Aventis |
156,445 |
5.7% |
195 ( ) |
Opana ER
| Endo Pharmaceuticals |
155,662 |
126.7% |
196 ( ) |
Zomig
| AstraZeneca Pharmaceuticals |
153,913 |
6.7% |
197 ( ) |
Humulin 70/30
| Eli Lilly and Company |
153,026 |
7.2% |
| 198 |
Prempro
| Pfizer Inc |
152,633 |
5.4% |
199 ( 9) |
Humulin N
| Eli Lilly and Company |
152,147 |
1.5% |
200 ( ) |
Xopenex HFA
| Sepracor Inc. (renamed Sunovion Pharmaceuticals Inc) |
151,919 |
25.8% |
|
All Others |
|
26,307,000 |
-15.0% |